Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab.

"Disclosure statement : E.C. reports grant/research support from Amgen, Bio-Cancer, Chugai Pharma, Ferring Pharmaceuticals, Novimmune, Pfizer, Roche and UCB; consultant fees from AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceuticals, Gilead, GlaxoSmithKline, Hospira, Ionis, Janssen, Jazz Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Merrimack Pharmaceutical, Napp, Novartis, Novimmune, ObsEva, Pfizer, R-Pharm, Regeneron Pharmaceuticals, Inc., Roche, SynAct Pharma, Sanofi Genzyme, Tonix and UCB; and is a member of speakers bureau for Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharma, Eli Lilly, Galapagos, Gilead, Hospira, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Sanofi-Aventis and UCB. V.B. received consulting fees from Amgen, Bristol-Myers Squibb, Gilead, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi and UCB and her host institution has received research grants from Amgen, the Cedar Hill Foundation and the National Institutes of Health. Y.L. has received research grants and/or consulting fees from Highland Instruments and Pfizer and holds stock and/or stock options in Cigna-Express Scripts. H.v.H., K.F. and A.P. are employees of Sanofi and may hold stock and/or stock options in the company. S.P. has received speaker fees/honoraria from Grunenthal, Menarini, MSD, Pfizer, Sanofi and UPSA. J.P. reports grant/research support from AbbVie, Bristol-Myers Squibb, Merck, Pfizer, Roche, UCB and Seattle Genetics; consultant fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, Eli Lilly, Medexus, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Teva and UCB. A.S. has received consulting fees from or participated in speakers’ bureaus for Genentech, Gilead, Eli Lilly, Regeneron Pharmaceuticals, Roche and Sanofi."

"Funding Funding was provided by Sanofi (Cambridge, MA, USA) and Regeneron Pharmaceuticals, INC. (Tarrytown, NY, USA). Disclosure statement: E.C. reports grant/research support from Amgen, Bio-Cancer, Chugai Pharma, Ferring Pharmaceuticals, Novimmune, Pfizer, Roche and UCB; consultant fees from AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceuticals, Gilead, GlaxoSmithKline, Hospira, Ionis, Janssen, Jazz Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Merrimack Pharmaceutical, Napp, Novartis, Novimmune, ObsEva, Pfizer, R-Pharm, Regeneron Pharmaceuticals, Inc., Roche, SynAct Pharma, Sanofi Genzyme, Tonix and UCB; and is a member of speakers bureau for Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharma, Eli Lilly, Galapagos, Gilead, Hospira, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Sanofi-Aventis and UCB. V.B. received consulting fees from Amgen, Bristol-Myers Squibb, Gilead, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi and UCB and her host institution has received research grants from Amgen, the Cedar Hill Foundation and the National Institutes of Health. Y.L. has received research grants and/or consulting fees from Highland Instruments and Pfizer and holds stock and/or stock options in Cigna-Express Scripts. H.v.H., K.F. and A.P. are employees of Sanofi and may hold stock and/or stock options in the company. S.P. has received speaker fees/honoraria from Grunenthal, Menarini, MSD, Pfizer, Sanofi and UPSA. J.P. reports grant/research support from AbbVie, Bristol-Myers Squibb, Merck, Pfizer, Roche, UCB and Seattle Genetics; consultant fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, Eli Lilly, Medexus, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, Teva and UCB. A.S. has received consulting fees from or participated in speakers’ bureaus for Genentech, Gilead, Eli Lilly, Regeneron Pharmaceuticals, Roche and Sanofi."

"Trial registrations NCT01061736, NCT02332590, NCT01709578, NCT01146652."